Literature DB >> 4191619

Shrinking the prostate.

.   

Abstract

Mesh:

Substances:

Year:  1970        PMID: 4191619      PMCID: PMC1699636     

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  11 in total

Review 1.  ANDROGEN METABOLISM.

Authors:  M B LIPSETT; S G KORENMAN
Journal:  JAMA       Date:  1964-11-23       Impact factor: 56.272

2.  Fractional analysis of urinary neutral 17-ketosteroids in relation to age.

Authors:  B W BROOKSBANK; A SALOKANGAS
Journal:  Acta Endocrinol (Copenh)       Date:  1959-02

3.  The effect of bilateral adrenalectomy on induced benign prostatic hyperplasia in mice.

Authors:  B Fingerhut; R J Veenema
Journal:  J Urol       Date:  1967-03       Impact factor: 7.450

4.  Effect of progestational agents on gonadal and adrenal cortical function in patients with benign prostatic hypertrophy and carcinoma of the prostate.

Authors:  J Geller; B Fruchtman; C Meyer; H Newman
Journal:  J Clin Endocrinol Metab       Date:  1967-04       Impact factor: 5.958

5.  The incidence of benign prostatic obstruction.

Authors:  B Lytton; J M Emery; B M Harvard
Journal:  J Urol       Date:  1968-05       Impact factor: 7.450

6.  The effect of polyene macrolides on the prostate gland and canine prostatic hyperplasia.

Authors:  H W Gordon; C P Schaffner
Journal:  Proc Natl Acad Sci U S A       Date:  1968-08       Impact factor: 11.205

7.  [Treatment of hypertrophy of the prostate with gestagens].

Authors:  W Vahlensieck; S Gödde
Journal:  Munch Med Wochenschr       Date:  1968-06-28

8.  Therapy with progestational agents in advanced benign prostatic hypertrophy.

Authors:  J Geller; A Angrist; K Nakao; H Newman
Journal:  JAMA       Date:  1969-11-24       Impact factor: 56.272

9.  The effects of amphotericin B on prostatic and testicular function in the dog.

Authors:  J H Texter; D S Coffey
Journal:  Invest Urol       Date:  1969-07

10.  [Animal experimental studies using 19-nor-17 alpha-hydroxyprogesterone caproate (Gestenoroncapronat) with respect to a possible therapeutic application in prostatic adenoma].

Authors:  J D Hahn; F Neumann; R Berswordt-Wallrabe
Journal:  Urologe       Date:  1968 Jul-Aug       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.